Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Downgrades Sapiens Intl Corp to Underweight

JP Morgan analyst Jackson Ader downgrades Sapiens Intl Corp (NASDAQ:SPNS) from Neutral to Underweight.

byBenzinga Newsdesk

December 14, 2021

1 minute read

JP Morgan analyst Jackson Ader downgrades Sapiens Intl Corp (NASDAQ:SPNS) from Neutral to Underweight.

Cathie Wood Continues To Show Faith In Bitcoin, Ethereum: Loads Up On 2 Crypto-Linked Stocks

By Rachit Vats

Today, 4:35 AM

Cathie Wood-led Ark Investment Management on Tuesday scooped up more shares in cryptocurrency-linked companies Coinbase Global Inc (NASDAQ: COIN) and Block Inc (NYSE: SQ) on the dip. &

$DOGE

Jefferies Downgrades Lumos Pharma to Hold, Announces $7 Price Target

By Benzinga Newsdesk

Today, 4:35 AM

Jefferies analyst Eun Yang downgrades Lumos Pharma (NASDAQ:LUMO) from Buy to Hold and announces $7 price target.

LUMO

Needham Maintains Buy on AtriCure, Lowers Price Target to $90

By Benzinga Newsdesk

Today, 4:35 AM

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $91 to $90.

ATRC

Avita Therapeutics Q3 EPS $(0.38) Beats $(0.40) Estimate, Sales $7.54M Down From $8.77M YoY

By Benzinga Newsdesk

Today, 4:35 AM

Avita Therapeutics (NASDAQ:RCEL) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.40) by 5 percent. This is a 46.15 percent decrease over losses of $(0.26) per share from

RCEL

JP Morgan Downgrades Sapiens Intl Corp to Underweight

Related Posts

Cathie Wood Continues To Show Faith In Bitcoin, Ethereum: Loads Up On 2 Crypto-Linked Stocks

Jefferies Downgrades Lumos Pharma to Hold, Announces $7 Price Target

Needham Maintains Buy on AtriCure, Lowers Price Target to $90

Avita Therapeutics Q3 EPS $(0.38) Beats $(0.40) Estimate, Sales $7.54M Down From $8.77M YoY